<DOC>
	<DOCNO>NCT02624843</DOCNO>
	<brief_summary>To establish therapeutic equivalence safety generic Benzyl Alcohol Lotion 5 % Ulesfia Lotion 5 % eradication head louse study subject .</brief_summary>
	<brief_title>Bioequivalence Study Benzyl Alcohol Lotion 5 % .</brief_title>
	<detailed_description />
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Benzyl Alcohol</mesh_term>
	<criteria>Healthy male nonpregnant female age 6 month upper age limit 60 year . Prospective participant upon examination confirm least 3 live head louse ( defined louse adult nymphs ) least 5 viable appearance louse egg ( nit ) . Prospective participant give write informed consent , participant 17 year age , whose parent/guardian give write informed consent participate study . Prospective participant available follow visit 21 day follow first treatment . Prospective female participant ( include female caregiver ) childbearing potential willing provide urine pregnancy test . Prospective participant agree shave hair use pediculicide , nit comb , louse treatment method course study . Prospective participant know sensitivity ingredient benzyl alcohol lotion 5 % ( HiTech Pharmacal Inc ) Ulesfia 5 % ( Shionogi Inc ) . Prospective participant know history irritation sensitivity pediculicides hair care product . Prospective participant secondary bacterial infection scalp ( eg . impetigo/pyoderma ) secondary long term scalp condition could make difficult evaluate extent severity infestation would present problem evaluation response therapy ( e.g. , psoriatic lesion scalp , extensive seborrheic dermatitis ) . Prospective participant treat head louse product within 4 week prior randomization . Prospective participant regularly shave hair , bleach hair , use permanent color hair , hair permanently straighten wave within previous 2 week . Prospective participant treat Trimethoprim contain product within previous 4 week , currently take course . Females pregnant , plan become pregnant , course study period , currently breast feed mother . Females childbearing potential unwilling use adequate method contraception least 4 week prior first application treatment 4 week last application treatment , unwilling take urine pregnancy test . Prospective participant participate another clinical study use investigational new drug within 1 month entry study . Participants already participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>